{"editorial":{"content_id":"d3a35b17-ea30-4845-b32a-df2c1018078b","slug":"4bio-sbim-20261024-231252","content_type":"news","title":"4BIO首次参加SBIm免疫接种大会，称疫苗市场份额约15%","summary":"巴西高复杂度药品分销商4BIO首次参加SBIm全国免疫接种大会，借机扩大疫苗市场布局。","body":"GRUPO PROFARMA旗下高复杂度药品分销商4BIO首次参加巴西免疫学会（SBIm）于10月21日至24日在里约热内卢举办的第28届全国免疫接种大会，据该公司自身数据，其疫苗市场份额约为15%。\n\n4BIO设有专门的疫苗业务部门，业务重点集中在机构渠道，服务专业化、高复杂度的需求，而非传统药品零售。公司表示，参加此次大会是其扩大疫苗领域布局战略的一部分。\n\n4BIO疫苗业务总监André Almeida在新闻稿中表示，这是公司首次以4BIO身份参加SBIm大会，目的是巩固市场存在、扩大与客户及医护专业人员的关系，并展示其在疫苗领域的业务。\n\n公司观察到疫苗市场正发生变化：历史上与儿童接种和专科诊所绑定的免疫剂市场，已扩大至成人群体，并进入实验室和药房连锁等新的分销渠道。据该公司称，这一变化反映出预防医学的升值以及对全生命周期健康保护的更多关注。\n\n针对主要影响成人和老年人的疾病（如带状疱疹）的免疫剂，在预防讨论和医护专业人员的建议中获得了更多空间。4BIO认为，对这类疾病认知的提升为不同疫苗接种渠道带来机会。\n\n4BIO隶属于GRUPO PROFARMA，该集团旗下还包括PROFARMA DISTRIBUIÇÃO和REDE D1000，业务覆盖16个州。4BIO开展三条业务线：特殊药品、注射美容和疫苗，重点是需要技术知识和差异化运营的产品。\n\n4BIO MEDICAMENTOS ESPECIAIS副总裁Vilson Schvartzman表示，加入GRUPO PROFARMA对4BIO而言是新篇章，公司保持为高复杂度药品提供专业解决方案的定位，如今拥有更稳固的结构来扩大业务、加强合作并为整个医疗行业创造价值。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","行业趋势","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-24T11:04:51.932Z","display_date":"2026-10-24","source_published_at":null,"source_url":"https://setorsaude.com.br/4bio-estreia-na-jornada-da-sbim-e-amplia-aposta-no-mercado-de-vacinas/","source_name":"Setor Saúde","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/4bio-sbim-20261024-231252","api_url":"https://chinabrazilinsight.com/api/public/content/4bio-sbim-20261024-231252","markdown_url":"https://chinabrazilinsight.com/api/public/content/4bio-sbim-20261024-231252?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/4bio-sbim-20261024-231252?view=json","last_updated":"2026-10-24T11:05:18.389Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}